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Background
The cystic fibrosis transmembrane conductance regulator
(CFTR) is the gene of interest in the eponymous disease,
cystic fibrosis (CF). CFTR is expressed in epithelial cells
and functions as a chloride channel. Several hundred
mutations are known to occur in CF patients, but the most
prevalent mutation is the deletion of phenylalanine at
position 508 (ΔF508). Although the mutated protein is
retained in the endoplasmic reticulum, the channel has
been shown to be at least in part functional. A possible
strategy for the treatment of CF therefore aims at facilitat-
ing surface expression by e.g. increasing total protein
expression or by chaperoning the protein on its route
from the endoplasmic reticulum to the cell surface. Poly-
morphisms in nitric oxide synthase (NOS) have been
shown to influence disease severity in CF patients.
Insights into the molecular mechanisms underlying the
disease modifying effect of NOS will not only help under-
standing variation in the clinical course of cystic fibrosis
but it may also provide information that can be exploited
to improve and individualize treatment strategies for CF
patients.
Results and conclusions
Using cell culture systems, we have investigated the effect
of NOS on CFTR expression levels. Preliminary results
show an up-regulation of wild-type and mutant CFTR by
two NOS isoforms. This CFTR up-regulation is independ-
ent of the enzymatic activity of NOS. Deletion of a C-ter-
minal PDZ domain interaction motif (TRL) does not
block NOS-mediated increase in CFTR expression. In
future experiments we will investigate if the observed up-
regulation of CFTR is mediated via a direct or indirect
interaction and if this enhanced expression translates into
a higher level of functional chloride channels formed by
CFTRΔF508 at the cell surface.
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